These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 29256624)
21. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Bessonova L; Volkova N; Higgins M; Bengtsson L; Tian S; Simard C; Konstan MW; Sawicki GS; Sewall A; Nyangoma S; Elbert A; Marshall BC; Bilton D Thorax; 2018 Aug; 73(8):731-740. PubMed ID: 29748252 [TBL] [Abstract][Full Text] [Related]
22. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor. Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527 [TBL] [Abstract][Full Text] [Related]
23. Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X. Pallin M; Daley CP J Cyst Fibros; 2020 Jan; 19(1):e3-e4. PubMed ID: 31771899 [No Abstract] [Full Text] [Related]
24. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Munce D; Lim M; Akong K Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556 [TBL] [Abstract][Full Text] [Related]
25. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC; Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024 [TBL] [Abstract][Full Text] [Related]
26. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial. Durmowicz AG; Lim R; Rogers H; Rosebraugh CJ; Chowdhury BA Ann Am Thorac Soc; 2018 Jan; 15(1):1-2. PubMed ID: 29020455 [TBL] [Abstract][Full Text] [Related]
27. Immeasurable Time Bias In Exposure to Ivacaftor. Sarayani A; Winterstein AG Health Aff (Millwood); 2019 Feb; 38(2):328. PubMed ID: 30715971 [No Abstract] [Full Text] [Related]
28. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519 [TBL] [Abstract][Full Text] [Related]
29. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269 [TBL] [Abstract][Full Text] [Related]
30. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
31. Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation. Burghard MM; Berkers GG; Ghijsen SS; Hollander-Kraaijeveld FF; de Winter-de Groot KK; van der Ent CK; Heijerman HH; Takken TT; Hulzebos HE Pediatr Pulmonol; 2020 Jun; 55(6):1400-1405. PubMed ID: 32233113 [TBL] [Abstract][Full Text] [Related]
32. Ivacaftor for cystic fibrosis. Barry PJ; Donaldson AL; Jones AM BMJ; 2018 May; 361():k1783. PubMed ID: 29773589 [No Abstract] [Full Text] [Related]
33. A safety evaluation of ivacaftor for the treatment of cystic fibrosis. McColley SA Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005 [TBL] [Abstract][Full Text] [Related]
34. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males. Secunda KE; Guimbellot JS; Jovanovic B; Heltshe SL; Sagel SD; Rowe SM; Jain M Am J Respir Crit Care Med; 2020 Apr; 201(8):996-998. PubMed ID: 31841644 [No Abstract] [Full Text] [Related]
35. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis. Kounis I; Lévy P; Rebours V Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601 [No Abstract] [Full Text] [Related]
36. Cystic Fibrosis: The Dawn of a New Therapeutic Era. Heltshe SL; Cogen J; Ramos KJ; Goss CH Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011 [No Abstract] [Full Text] [Related]
37. Cystic Fibrosis-related Diabetes Is Associated with Worse Lung Function Trajectory despite Ivacaftor Use. Bengtson CD; He J; Kim MD; Salathe MA Am J Respir Crit Care Med; 2021 Dec; 204(11):1343-1345. PubMed ID: 34469275 [No Abstract] [Full Text] [Related]
38. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. Talamo Guevara M; McColley SA Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049 [TBL] [Abstract][Full Text] [Related]
39. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Nichols AL; Davies JC; Jones D; Carr SB Paediatr Respir Rev; 2020 Sep; 35():99-102. PubMed ID: 32386958 [TBL] [Abstract][Full Text] [Related]